KALAMAZOO, Mich. / Jun 03, 2024 / Business Wire / Stryker (NYSE: SYK), a global leader in medical technologies, announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. The acquisition will strengthen Stryker’s offerings in the soft tissue fixation segment and highlights Stryker’s commitment to providing differentiated solutions for ligament and tendon reconstruction.
Artelon’s technologies complement and expand the current range of products available to Stryker’s foot and ankle and sports medicine specialist customers. Its differentiated synthetic technology is designed to enhance biological and mechanical ligament and tendon reconstruction, with over 60,000 implantations worldwide. The acquisition will also allow Stryker to position itself more competitively in the foot and ankle and sports medicine segment with an innovative biomaterial technology that supports the healing of the patient’s soft tissues.
“Artelon’s proven product portfolio and differentiated offerings will enhance our ability to innovate and serve our customers,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “The addition of Artelon’s products to our already robust foot and ankle and sports medicine product portfolios will fuel our goal of establishing comprehensive offerings for customers in these segments. We share a common dedication to integrity, quality, and advancing the knowledge of healthcare providers to achieve the best clinical outcomes and rebuild patients’ lives.”
This transaction is subject to customary closing conditions. Stryker and Artelon will continue to operate as separate entities and proceed with business as usual until the transaction closes.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Last Trade: | US$394.22 |
Daily Change: | 9.39 2.44 |
Daily Volume: | 868,660 |
Market Cap: | US$150.710B |
July 31, 2025 May 01, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load